FACT SHEET

About Us

Founded in 2017, Sonic Incytes Medical Corp. is a privately held health technology company headquartered in Vancouver, Canada. Our lead product, Velacur™, entered the US market in early 2021.

At Sonic Incytes, we believe in creating accessible and affordable solutions for healthcare providers with health insights they can count on to improve patient care. Nowhere in medicine is this more applicable than the silent health crisis of chronic liver disease.

Affecting 100 million Americans by 2030, and millions more around the world, chronic liver disease is an emerging global health crisis.

Healthcare practitioners are not well equipped to manage this disease because existing diagnostic tools are either expensive, inefficient, inaccessible or inaccurate.

Recognizing the rise of chronic liver disease, we've made it our mission to reduce the disease by enabling routine assessment and management of liver health with our breakthrough, point of care ultrasound solution, Velacur™.

Velacur™ is redefining the standard of care in quantifying chronic liver disease with diagnostic accuracy comparable to MRI.

Key Events

2017
Company Founded

2018
Feasibility Study Completed

2019
Pivotal Study Initial Data Release

2020
$3.5M Seed Raise

FDA Clearance

Pivotal Study Comparison to MRI Data Release

2021
Velacur™ Commercial Launch

Leadership Team

George Aliphtiras
CEO

Former CEO and Founder, BioMers

Dr. Tim Salcudean
Co-founder / CTO

University of British Columbia Professor, Laszlo Chair in ultrasound and robotics

Dr. Robert Rohling
Co-founder / CSO

University of British Columbia Professor, ICICS Director in ultrasound and AI

Michael Yang
CFO

Formerly with Lush Cosmetics, Teradici & CHC

Brian Stachniak
Director of Product

Former Manager, McKesson Imaging

Jeffrey Haar
Director of Sales

Former Sales Manager, Diversatek Healthcare and Sandhill Scientific (FibroScan)

Board of Directors

Dr. Kenneth Moritsugu
Former US Deputy Surgeon General, Rear Admiral US Public Health Service

Paul Geyer
CEO, Discovery Parks and Nimbus Synergies

Daniel Cordingley
Former CEO and Founder, Teradici

Natalie Dakers
Former CEO and Founder, Accel-Rx and CDRD

FACT SHEET

SonicIncytes
Health Insights You Can Count On

Our Strategy

- Develop quantitative ultrasound for point-of-care applications

- Provide advanced diagnostic capabilities comparable to MRI elastography using handheld ultrasound

- Partner with leading clinical research institutions and industry in Canada, the US and internationally

- First commercial application: chronic liver disease, consisting of NAFLD/NASH, autoimmune, viral, and transplant

- Prioritized markets: North America, Asia and Europe

- Future clinical applications: various fibrotic diseases (liver, kidney, etc.) and cancer (liver, prostate, etc.) and other disorders

Development Pipeline – Application Readiness

Product	Program	Technology	Feasibility	Pivotal	Regulatory	Commercial
Velacur™ (Liver)	Chronic Liver Disease (NASH)					
Velacur™ (Liver)	Transplant (Inflammation)					
Velacur™ (Liver)	Cancer (Lesion)					
Kidney	Chronic Kidney Disease					
Reproductive	Cancer					

Velacur™

Velacur™ is the first handheld 3D liver tissue assessment tool with diagnostic accuracy comparable to MRI, the current non-invasive gold standard. Our proprietary technology uses steady state waves, the same used by MRI elastography, to quantify liver disease, paving the way for a non-invasive, low-cost and scalable solution to assess and manage millions of patients.

Velacur™ consists of a handheld ultrasound and an activation pad. The patient lies on the activation pad, which creates steady state waves in the liver, and a 3D tissue sample is measured using the ultrasound probe.

The entire procedure takes about five minutes in a doctor's office, providing for a quick, safe and comfortable patient experience. Results are available immediately, and its portability allows physicians to integrate it into multiple practice settings with ease.

With minimal upfront investment, a potential new revenue stream for physicians, and a procedure simple enough to be delegated by the physician, Velacur™ offers a cost-effective solution and improved patient management for this burgeoning disease.

US Fatty Liver Disease Market Quick Facts

Prevalence:

1 in 3 Americans (100 Million)

Healthcare Costs:

$103B / Annum

Diagnostic Market Size:

$2B